Research Radboudumc Technology Centers Radboud Biobank News Biobank Opt-out versus Opt-In Consent for Residual Samples

17 October 2019

The Blue Diamond Gallery Residual samples, i.e. biomaterial leftover from standard clinical procedures, constitute a critical resource for the biobanking community.

Residual material refers to biomaterials leftover from standard clinical procedures as well as clinical imaging and associated medical data. These types of samples are critical for biobanking research and education within the Radboudumc. To date, the hospital has relied on an opt-out method of consent, which means samples are available for scientific research unless a patient explicitly objects. The Radboud Biobank will be conducting a 6-month feasibility study, as proposed by the Netherlands Federation of University Medical Centers (NFU), to evaluate the impact of migrating to a opt-in method, which requires explicit consent from the patient for use of the residual material. This feasibility study will be restricted to new patients (approximately 500 per week) and will exclude those who are comatose, incapacitated, <16 years of age, or admitted for acute care. Eligible new patients will be asked for their consent while registering at the Central Registration Desk. Their responses will be immediately recorded in their Electronic Health Record (Epic). Patients who are unable to decide during their registration will be contacted by a Radboud Biobank representative within two weeks to clarify concepts and answer remaining questions. All patients will be able to withdraw their consent in their personal electronic chart (MijnRadboud). At pre-defined points during the feasibility study, the Radboud Biobank will examine the distribution of responses by key sociodemographic characteristics to explore obstacles in an opt-in consent process. For more information on the use of residual material in the Radboudumc, please visit the Radboud Biobank website. There is also a poster available with more information.
  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud biobank

Related news items


Farewell Dorine Swinkels

1 September 2026

On Friday, September 4th, 2026, Dorine Swinkels will retire as Professor of Experimental Clinical Chemistry at Radboudumc. She is also leaving the Radboud Biobank.

go to page

Greening Radboud Biobank – reduction number of aliquots in storage for future initiatives

1 September 2026

Like LUMC and NKI, the Radboud Biobank will also store fewer aliquots per collection tube.

go to page

Effect of Fit & Funding on external invoices

1 September 2026

The Radboud Biobank not only manages issuances and projects for Radboudumc but also provides external services. The Radboud Biobank invoices the external organization for these services.

go to page

New link between iLES and Castor EDC connects clinical data and biobank material

1 September 2026

The Biobank Information Management System, iLES, is now linked to Castor EDC. This development was realized within a KWF-funded project.

go to page

Radboud Biobank's 2025 annual report

3 March 2026

The Radboud Biobank's 2025 annual report is now available on request.

go to page

Aevai Health developed a virtual assistant

3 March 2026

Aevai Health has developed Alva - a virtual assistant to engage research participants, which can support participants with health literacy, understanding research protocols, and with using measurement devices.

go to page